VOR.NASDAQVor Biopharma INC

SCHEDULE: Major Investor Cuts VOR Biopharma Stake to 20.1%

Sentiment:

Beneficial Ownership Amendment

📋All filings for Vor Biopharma INC
🔒Login to Follow

Reprogrammed Interchange LLC and Reid Hoffman have significantly reduced their beneficial ownership in VOR Biopharma Inc. to 20.1% through recent open market sales.

Worse than expectedReprogrammed Interchange LLC and Reid Hoffman, significant beneficial owners, have reduced their stake in VOR Biopharma Inc. to 20.1% through consistent open market sales, indicating a potential loss of confidence or strategic divestment.

Summary

  • Reprogrammed Interchange LLC and Reid Hoffman, as Reporting Persons, filed Amendment No. 6 to their Schedule 13D regarding VOR BIOPHARMA INC. common stock.
  • Beneficial ownership decreased by more than one percent of the outstanding shares of Common Stock due to open market sales.
  • The Reporting Persons now collectively beneficially own 1,374,775 shares of VOR Biopharma Inc. common stock.
  • This aggregate amount represents 20.1% of the issuer's class of securities.
  • Sales occurred from August 25, 2025, through October 9, 2025, with specific transactions detailed, including a 1-for-20 reverse stock split effected on September 18, 2025.

Sentiment

Score: 3

Explanation: The consistent and significant divestment by a major investor, Reprogrammed Interchange LLC and Reid Hoffman, indicates a negative sentiment or strategic exit, which could be perceived negatively by the market.

Negatives

  • Reprogrammed Interchange LLC and Reid Hoffman, significant beneficial owners, have consistently sold shares in VOR Biopharma Inc. over several weeks.
  • The beneficial ownership has decreased by more than one percent of the outstanding shares, indicating a significant divestment.

Risks

  • The consistent selling by a major beneficial owner could signal a lack of confidence in the company's future prospects, potentially leading to negative market sentiment.
  • Significant divestment by a large shareholder may put downward pressure on the stock price.

Stakeholder Impact

  • Shareholders may experience a decline in stock price due to the perceived lack of confidence from a major investor and the increased supply of shares in the market.

Key Dates

DateDescription
January 7, 2025Original Schedule 13D filed with the SEC.
August 25, 2025Reprogrammed Interchange LLC sold 19,367 shares at $42.3256 per share.
August 26, 2025Reprogrammed Interchange LLC sold 14,209 shares at $41.6165 per share.
August 27, 2025Reprogrammed Interchange LLC sold 30,582 shares at $40.1057 per share.
August 28, 2025Reprogrammed Interchange LLC sold 40,317 shares at $40.2307 per share.
August 29, 2025Amendment No. 1 to Schedule 13D filed with the SEC.
September 3, 2025Reprogrammed Interchange LLC sold 27,730 shares at $39.9222 per share.
September 4, 2025Reprogrammed Interchange LLC sold 22,650 shares at $38.5709 per share.
September 5, 2025Reprogrammed Interchange LLC sold 20,000 shares at $39.3639 per share.
September 8, 2025Reprogrammed Interchange LLC sold 23,221 shares at $39.7949 per share.
September 9, 2025Reprogrammed Interchange LLC sold 22,461 shares at $40.0084 per share; Amendment No. 2 to Schedule 13D filed with the SEC.
September 10, 2025Reprogrammed Interchange LLC sold 17,500 shares at $36.3019 per share.
September 11, 2025Reprogrammed Interchange LLC sold 14,240 shares at $36.6151 per share.
September 12, 2025Reprogrammed Interchange LLC sold 15,000 shares at $35.0811 per share; Amendment No. 3 to Schedule 13D filed with the SEC.
September 15, 2025Reprogrammed Interchange LLC sold 20,000 shares at $32.815 per share.
September 16, 2025Reprogrammed Interchange LLC sold 22,363 shares at $30.8023 per share.
September 18, 20251-for-20 reverse stock split of VOR Biopharma Inc. Common Stock effected.
October 1, 2025Reprogrammed Interchange LLC sold 1,400 shares at $39.1925 per share.
October 2, 2025Reprogrammed Interchange LLC sold 32,451 shares at $39.828 per share.
October 3, 2025Reprogrammed Interchange LLC sold 7,901 shares at $37.832 per share.
October 6, 2025Reprogrammed Interchange LLC sold 70,763 shares at $37.0079 per share; Amendment No. 4 to Schedule 13D filed with the SEC.
October 7, 2025Reprogrammed Interchange LLC sold 27,624 shares at $33.8369 per share.
October 8, 2025Date of event requiring filing of this statement; Reprogrammed Interchange LLC sold 75,262 shares at $33.8651 per share; Amendment No. 5 to Schedule 13D filed with the SEC.
October 9, 2025Reprogrammed Interchange LLC sold 48,884 shares at $32.068 per share.
October 10, 2025Filing date of Amendment No. 6 to Schedule 13D.

Recommendation

sell

The consistent and significant divestment by a major beneficial owner, Reprogrammed Interchange LLC and Reid Hoffman, suggests a lack of confidence or a strategic exit. This could put downward pressure on the stock price and warrants caution for current and potential investors, making a 'sell' recommendation appropriate for those holding the stock.

Keywords

VOR Biopharma, Reprogrammed Interchange LLC, Reid Hoffman, Schedule 13D, Beneficial Ownership, Stock Sales, Biopharma, Insider Selling

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.